Mona AlQazzaz is a community engagement scientific fellow and alliance manager at YCharOS and the Structural Genomics Consortium, an open-science effort to solve protein structures.
Mona AlQazzaz
Community engagement scientific fellow and alliance manager
YCharOS and the Structural Genomics Consortium
From this contributor
We found a major flaw in a scientific reagent used in thousands of neuroscience experiments — and we’re trying to fix it.
As part of that ambition, we launched a public-private partnership to systematically evaluate antibodies used to study neurological disease, and we plan to make all the data freely available.
Explore more from The Transmitter
Neuroscience Ph.D. programs adjust admissions in response to U.S. funding uncertainty
Some departments plan to shrink class sizes by 25 to 40 percent, and others may inadvertently accept more students than they can afford, according to the leaders of 21 top U.S. programs.
Neuroscience Ph.D. programs adjust admissions in response to U.S. funding uncertainty
Some departments plan to shrink class sizes by 25 to 40 percent, and others may inadvertently accept more students than they can afford, according to the leaders of 21 top U.S. programs.
By
Claudia López Lloreda, Calli McMurray
3 March 2025 | 7 min read
Keeping it personal: How to preserve your voice when using AI
To harness the workmanlike prose of artificial intelligence while maintaining a recognizable style, use it as an analyzer rather than as a writer.
Keeping it personal: How to preserve your voice when using AI
To harness the workmanlike prose of artificial intelligence while maintaining a recognizable style, use it as an analyzer rather than as a writer.
By
Tim Requarth
3 March 2025 | 12 min read
Null and Noteworthy, relaunched: Probing a schizophrenia biomarker
This edition of Null and Noteworthy—the first for The Transmitter—highlights new findings about the auditory steady-state response in people with schizophrenia that, all within one study, somehow packed in a null result and a failed replication.
Null and Noteworthy, relaunched: Probing a schizophrenia biomarker
This edition of Null and Noteworthy—the first for The Transmitter—highlights new findings about the auditory steady-state response in people with schizophrenia that, all within one study, somehow packed in a null result and a failed replication.
By
Laura Dattaro
28 February 2025 | 5 min read